Consort diagram. A total of 498 children were enrolled on frontline protocol Total XV. Of these, 410 patients (pts) had evaluable anti–asparaginase antibody (Ab), and 339 patients had evaluable dexamethasone apparent oral clearance data, measured at week 8 of continuation phase of therapy. Dexamethasone pharmacokinetics were previously reported for a subset of 214 patients.³